Fig. 4From: Hyperprogression after immunotherapy in patients with malignant tumors of digestive systemVariation of the tumor burden in the five hyperprogressors. Tumor burden is compared from about 2 months before immunotherapy (pre-baseline) to image immediately before immunotherapy (baseline), and then to first imaging after immunotherapy (post-baseline). Tumor burden was evaluated with irRECISTBack to article page